Analysts expect Bank of Marin Bancorp (NASDAQ:BMRC) to report $0.86 EPS on January, 22.They anticipate $0.07 EPS change or 7.53% from last quarter’s $0.93 EPS. BMRC’s profit would be $5.92 million giving it 20.71 P/E if the $0.86 EPS is correct. After having $0.88 EPS previously, Bank of Marin Bancorp’s analysts see -2.27% EPS growth. The stock decreased 0.63% or $0.45 during the last trading session, reaching $71.25. About 13,490 shares traded. Bank of Marin Bancorp (NASDAQ:BMRC) has risen 24.62% since January 14, 2017 and is uptrending. It has outperformed by 7.92% the S&P500.
Among 3 analysts covering Avinger (NASDAQ:AVGR), 0 have Buy rating, 0 Sell and 3 Hold. Therefore 0 are positive. Avinger had 3 analyst reports since December 29, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Tuesday, December 29 by Dougherty & Company. The firm has “Perform” rating given on Wednesday, April 12 by Oppenheimer. The stock has “Hold” rating by Canaccord Genuity on Tuesday, April 11. See Avinger, Inc. (NASDAQ:AVGR) latest ratings:
Bank of Marin Bancorp operates as the holding firm for Bank of Marin that provides a range of financial services primarily to professionals, small and middle-market businesses, and individuals in California. The company has market cap of $490.33 million. The firm accepts personal and business checking and savings accounts; time deposits, such as time certificates of deposit, individual retirement accounts, health savings accounts, and certificate of deposit account registry service; and insured cash sweep accounts. It has a 21.4 P/E ratio. It also offers commercial real estate, commercial and industrial, and consumer loans, as well as construction financing and home equity lines of credit.
Among 4 analysts covering Bank of Marin Bancorp (NASDAQ:BMRC), 0 have Buy rating, 0 Sell and 4 Hold. Therefore 0 are positive. Bank of Marin Bancorp has $74.0 highest and $51 lowest target. $72.67’s average target is 1.99% above currents $71.25 stock price. Bank of Marin Bancorp had 11 analyst reports since October 19, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Hold” on Monday, July 10. Piper Jaffray maintained it with “Hold” rating and $6800 target in Friday, July 28 report. The rating was maintained by Keefe Bruyette & Woods on Thursday, December 21 with “Hold”. The stock has “Neutral” rating by Piper Jaffray on Wednesday, January 18. The firm has “Hold” rating given on Tuesday, November 28 by Piper Jaffray. On Tuesday, August 1 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. Keefe Bruyette & Woods maintained it with “Hold” rating and $6800 target in Monday, June 26 report.
Investors sentiment decreased to 1.47 in Q3 2017. Its down 0.03, from 1.5 in 2017Q2. It fall, as 7 investors sold Bank of Marin Bancorp shares while 23 reduced holdings. 14 funds opened positions while 30 raised stakes. 2.73 million shares or 7.20% more from 2.55 million shares in 2017Q2 were reported. Banc Funds Communications Lc invested in 147,365 shares. Sg Americas Ltd Liability holds 0% of its portfolio in Bank of Marin Bancorp (NASDAQ:BMRC) for 1,656 shares. 10,221 were reported by Anchor Cap Advisors Limited Liability Co. American Gp Inc invested in 4,016 shares or 0% of the stock. Credit Suisse Ag reported 4,039 shares. Tiaa Cref Inv Mngmt Ltd Liability Corp, a New York-based fund reported 15,198 shares. New York-based Products Prtnrs Limited Co has invested 0.02% in Bank of Marin Bancorp (NASDAQ:BMRC). National Bank Of Mellon Corp reported 25,706 shares or 0% of all its holdings. Private Ocean Limited Liability Co holds 0.15% or 3,619 shares. First Trust Advsr L P has 0% invested in Bank of Marin Bancorp (NASDAQ:BMRC). Tower Lc (Trc) has 0% invested in Bank of Marin Bancorp (NASDAQ:BMRC). Manufacturers Life Ins The stated it has 244,506 shares. California State Teachers Retirement stated it has 9,665 shares. Citigroup Incorporated has 366 shares. Rhumbline Advisers invested 0% of its portfolio in Bank of Marin Bancorp (NASDAQ:BMRC).
Avinger, Inc., a commercial-stage medical device company, designs, makes, and sells image-guided and catheter systems used by physicians to treat patients with peripheral arterial disease in the United States and Europe. The company has market cap of $6.40 million. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. It currently has negative earnings. The companyÂ’s lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.